Eisai R&d Management Co., Ltd.

Betty Chan

John JianShi Wang

Guo Zhu Zheng

Yoshihiko Kotake

Gregg F Keaney

Peter G Smith

Kazunobu Kira

Parcharee Tivitmahaisoon

Sudeep Prajapati

Norio Murai

Silvia Buonamici

Baudouin Gerard

Lihua Yu

Xiang Liu

Ermira Pazolli

Satoshi Nagao

Masayuki Miyano

Kian Huat Lim

Eunice Sun Park

Nicholas C Gearhart

Regina Mikie Kanada Sonobe

Michael P Thomas

Kenzo Arai

Atsushi Endo

Arani Chanda

Regina Mikie Kanada Sonabe

Regina Kanada Sonobe

Sundeep Prajapati

The present disclosure provides a novel solid state form of pladienolide pyridine compounds having Formula I, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful. 

Crystalline form of (2S,3S,6S,7R,10R,E)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-((R,2E,4E)-6-(piridin-2-yl)hepta-2,4-dien-2-yl)oxacyclododec-4-en-6-yl-4-methylpiperazine-1-carboxylate and methods of use thereof

The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.

Pladienolide pyridine compounds and methods of use

Growing community of inventors

Harvard, MA, United States of America

Betty Chan